Slide 1: First Quarter Fiscal Year 2010 Conference Call
Exhibit 99.1 Simulations Plus, Inc. NASDAQ: SLP First Quarter Fiscal Year 2010 Conference Call January 13, 2010
Slide 2: Introduction and Welcome
Introduction and Welcome • Introduction and Welcome • Agenda – First Quarter FY 2010 (1QFY10) Financial Summary – Progress in Business Units – Strategy Going Forward – Questions and Answers
Slide 3: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ si
Slide 4: 1QFY10 (3 months) Financial Summary
1QFY10 (3 months) Financial Summary • Gross revenues = $2.437 MM (up 14.2% from 1QFY09) – Pharmaceutical software and services = $1.735 MM (up 21.3% from $1.430 MM in 1QFY09) – Words+ subsidiary = $702,000 (down 0.1% from $703,000 1QFY09) • SG&A = $1,004,000 (up 11.1% from $904,000 in 1QFY09) – SG&A
Slide 5: Share Repurchase Program
Share Repurchase Program • Board of directors authorized share repurchase program for up to $2.5 million from October 2008 through October 2009. Actual repurchases began December 2, 2008, so the board extended the repurchase period through December 1, 2009. • Total of 1.02 MM shares were bought back
Slide 6: Progress - ADMET Predictor
Progress - - 1 • ADMET Predictor™ (Structure-property prediction program) – Version 4.0 was released in July with new metabolism and toxicity models – New Dose Optimization Module developed under estimates dose amount needed for new molecules based on mini-GastroPlus simulation • Developed under Pfi
Slide 7: Solubility in Biorelevant Fluids
Solubility in Biorelevant Fluids • During FY09 we funded a series of experiments with Northeastern University to measure the solubility of 160 drugs and drug-like compounds in three different types of biorelevant fluids: – Fasted state simulated gastric fluid (FaSGF) – Fasted state simulated intesti
Slide 8: Progress - ClassPharmer
Progress - - 2 • ClassPharmer™ (Data Mining and de novo Molecule Design) – Numerous improvements were being incorporated during the 4th quarter, and Version 4.7 was released in October. – We continue to enhance ClassPharmer’s capabilities in data mining and de novo molecule design (design of new mol
Slide 9: Progress - DDDPlus
Progress - - 3 DDDPlus - Simulates laboratory dissolution experiments Sales continue to increase steadily Version 3.0 was released in Q3 with a number of important enhancements Remains the only tool of its kind Further development on hold during 1QFY10 to allow greater support for contract studies
Slide 10: Progress - GastroPlus
Progress - - 4 • GastroPlus™ – Development of Drug-drug Interaction module continues under funded collaboration with Roche - initial capability is now in use at Roche. Full capability to be released with Version 7.0. – Development of ocular delivery capability under a funded collaboration with Pfize
Slide 11: GastroPlus Ocular Delivery - Funded Collaboration with Pfizer
GastroPlus Ocular Delivery - Funded Collaboration with Pfizer
Slide 12: GastroPlus Pulmonary Delivery - Funded Collaboration with GlaxoSmithKline
GastroPlus Pulmonary Delivery - Funded Collaboration with GlaxoSmithKline
Slide 13: Progress - Words+ subsidiary
Progress - - 5 • Words+ subsidiary – General economy appears to be affecting this business - many states are struggling, and a large percentage of our sales come from 3rd-party sources (Medicaid, Medicare, schools, state vocational rehabilitation programs, etc.) – New Conversa™ communication device
Slide 14: Miscellaneous Items
Miscellaneous Items • Potential acquisition we were working on for a number of months did not go through - - seller decided to go with another buyer. Potential remains to acquire software part of the business, which was our primary interest. • Due diligence currently in progress on three acquisition
Slide 15: Strategy Going Forward
Strategy Going Forward • Continue to expand product line and services – Pharmaceutical software and services • Continue to expand Life Sciences team – For several new product development projects in our corporate strategic plan – To increase capacity to conduct consulting studies and funded collabor
Slide 16: Additional Factors
Additional Factors • State of the pharmaceutical industry – Mergers have had no adverse effect on business to date - in fact licenses have increased at the larger companies, academic and government organizations. – Large companies continue to adopt in silico (software) technologies in various depart
Slide 17: Summary
Summary • Simulations Plus financial strength continues – Excellent cash position that continues to grow – No debt • Record first quarter! Strong marketing and sales efforts starting to show results – Pharmaceutical software and services revenues up 21.3% from 1QFY09 – Words+ subsidiary flat for the
Slide 18: Questions?
Questions? simulations plus, inc. oe
Slide 19: Slide 19